Loading…

Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?

In an attempt to study the optimal combination of a phenyl ring at the C²-position and different substituents at the N⁵- and N⁸-positions towards the selective modulation of human A₃ adenosine receptors (hA₃AR), we synthesized a new series of 2-para-(un)substituted-phenyl-pyrazolo-triazolo-pyrimidin...

Full description

Saved in:
Bibliographic Details
Published in:Bioorganic & medicinal chemistry 2011-10, Vol.19 (20), p.6120-6134
Main Authors: Cheong, Siew Lee, Dolzhenko, Anton V, Paoletta, Silvia, Lee, Evelyn Pei Rong, Kachler, Sonja, Federico, Stephanie, Klotz, Karl-Norbert, Dolzhenko, Anna V, Spalluto, Giampiero, Moro, Stefano, Pastorin, Giorgia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In an attempt to study the optimal combination of a phenyl ring at the C²-position and different substituents at the N⁵- and N⁸-positions towards the selective modulation of human A₃ adenosine receptors (hA₃AR), we synthesized a new series of 2-para-(un)substituted-phenyl-pyrazolo-triazolo-pyrimidines bearing either a methyl or phenylethyl at N⁸ and chains of variable length at N⁵. Through biological evaluation, it was found that the majority of the compounds had good affinities towards the hA₃AR in the low nanomolar range. Compound 16 possessed the best hA₃AR affinity and selectivity profile (KᵢhA₃=1.33nM; hA₁/hA₃=4880; hA₂A/hA₃=1100) in the present series of 2-(substituted)phenyl-pyrazolo-triazolo-pyrimidine derivatives. In addition to pharmacological characterization, a molecular modeling investigation on these compounds further elucidated the effect of different substituents at the pyrazolo-triazolo-pyrimidine scaffold on affinity and selectivity to hA₃AR.
ISSN:0968-0896
1464-3391
DOI:10.1016/j.bmc.2011.08.026